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ABSTRACT
Introduction: Although some differences
between individual dipeptidyl peptidase-4
(DPP-4) inhibitors may exist, the National
Institute for Health and Clinical Excellence
(NICE) have recommended that ‘prescribers
should be encouraged to select the individual
DPP-4 inhibitor with the lowest acquisition cost
available to them, where all other factors are
equal’. We aimed to determine whether or not
‘within class’ switching to alogliptin, the DPP-4
inhibitor with lowest acquisition cost, is a
clinically appropriate strategy.
Methods: This study evaluated people with
type 2 diabetes taking DPP-4 inhibitor therapy
in addition to at least one other diabetes ther-
apy. Primary care records were reviewed from
six clinical commissioning groups (CCGs). For
people who had been switched from other DPP-
4 inhibitors to alogliptin, an assessment of the
impact of switch on both absolute haemoglobin
A1c (HbA1c) levels and on HbA1c trajectory was
undertaken. Persistence on alogliptin and the
need for therapy intensification was also
assessed.
Results: Overall, 865 people with diabetes met
the eligibility criteria for the study. There was
no significant difference between pre- and post-
switch mean HbA1c level [8.44% (SD 1.52%) vs
8.42% (1.62%), p = 0.6]. Similarly, for patients
where there was sufficient data to assess the
impact of switching on HbA1c trajectory
(n = 319) minimal impact was identified (actual
HbA1c at 3 months 8.33% vs projected 8.31%).
The majority of people with diabetes (80.76%)
remained on alogliptin treatment at 6 months
and only 4.54% required additional diabetes
therapies. Switching to alogliptin resulted in a
median saving of £7.24 per patient-month.
Conclusion: Switching United Kingdom (UK)
primary care patients from other DPP-4 inhibi-
tors to alogliptin did not result in a statistically
significant or clinically meaningful change in
HbA1c level and few required the addition of
further diabetes therapies, suggesting that
therapy change or intensification was not
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INTRODUCTION
The management of type 2 diabetes (T2DM) is
becoming increasingly complex. Globally,
around 1 in 11 people have diabetes; 90% of
them have T2DM [1]. In the UK, approximately
3.7 million people have been diagnosed with
diabetes as of November 2017 [2]. Initial man-
agement may involve lifestyle and dietary
modifications only, but progressive intensifica-
tion of pharmacological therapy—usually start-
ing with metformin as first-line treatment—is
recommended if adequate glycaemic control is
not achieved [3]. Although there is growing
evidence for the use of glucagon-like peptide 1
(GLP-1) analogues and sodium-glucose co-
transporter-2 (SGLT-2) inhibitors in people with
proven atherosclerotic disease or heart failure,
in early diabetes the emphasis remains on con-
trolling hyperglycaemia. In early disease,
dipeptidyl peptidase-4 (DPP-4) inhibitors are
seen as a good option after metformin in pri-
mary care as they are perceived as an oral ther-
apy with a reassuring safety profile and with a
low risk of hypoglycaemia, as well as being
neutral in terms of body weight. Within the
class, it has been suggested that there may be
some differences in efficacy on the basis of the
individual registration studies. There are no
head-to-head studies; however, after adjust-
ment for baseline glycaemic control, the impact
on HbA1c was broadly consistent across the
registration studies [4–8], and the outcomes of
the cardiovascular safety trials demonstrated
very similar outcomes in people with estab-
lished cardiovascular disease [9–11]. Therefore,
the National Institute for Health and Clinical
Excellence (NICE) guidelines state that ‘recom-
mendations should consistently refer to DPP-4
inhibitors as a class’ and recommend ‘that pre-
scribers should be encouraged to select the
individual DPP-4 inhibitor with the lowest
acquisition cost available to them, where all
other factors are equal’. However, given the
inconclusive and somewhat limited evidence
available at the time of guideline development,
NICE considered the interchangeability of DPP-
4 inhibitors to be uncertain [3].
Some local clinical commissioning groups
(CCGs) have recommended implementing a
within-class therapy switch to the least costly
DPP-4 inhibitor, alogliptin, in people with
T2DM. Other CCGs have delayed making
wholesale switches as there is some uncertainty
around the interchangeability of DPP-4 inhibi-
tors; it is unclear if people switched from one
DPP-4 inhibitor to another in routine clinical
practice for cost reasons maintain adequate
glycaemic control. This study aimed to address
this uncertainty by collecting real-world evi-
dence regarding clinical effectiveness results of
this cost-driven treatment switch.
METHODS
We performed a retrospective, observational
cohort study which was based on anonymised
Read code data routinely captured in primary
care systems, extracted for all people with
T2DM that were moved to alogliptin from an
alternative DPP-4 inhibitor within six CCG
localities (Newbury and District, South Reading,
North and West Reading, Wokingham, Great
Yarmouth and Waverley, and Mid Essex).
Switch programs to alogliptin from alternative
DPP-4 inhibitors at the discretion of the indi-
vidual general practitioner took place in all
these CCG areas. Anonymised data was extrac-
ted from the Electronic Care Leading to
Improved Patient Safety and Empowerment
(ECLIPSE) computer system which accesses
individual patient records, provides prescribers
with prescribing safety alerts, information on
cost and availability of medications and cost of
referrals to secondary care specialists, as well as
data pertaining to hospital admissions and
outpatient visits. This analysis was performed
with the approval of the Caldicott Guardians
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from the respective CCGs, the UK Confiden-
tiality Advisory Group and the South West
Regional Ethics Committee (approval number
17/SW/001) in accordance with the principles
of the Helsinki Declaration of 1964 and its fur-
ther amendments.
Eligibility
Adults (aged C 18 years) with diabetes and a
complete set of baseline characteristics recorded
in the database that were switched to alogliptin
within the licensed indication [8], from an
alternative DPP-4 inhibitor and had at least one
HbA1c value prior to the switch (index date)
and one post-index HbA1c recorded, with the
post-index HbA1c assessment taking place at
least 76 days (2.5 months) post index-date, were
eligible for inclusion. People switched from
existing DPP-4 inhibitor monotherapy were
excluded from the main analyses reported in
this paper, since alogliptin is not licensed for
use as monotherapy in the UK.
Primary Endpoint
The primary objective of this study was to ret-
rospectively estimate the clinical impact of
switching people with T2DM from their current
DPP-4 inhibitor to alogliptin based on two co-
primary endpoints: (1) change from pre- to
post-switch HbA1c level and (2) deviation of
post-switch HbA1c from HbA1c trajectory,
where projected HbA1c was derived from a sta-
tistical model including more than one assess-
ment of pre-switch HbA1c (in order to generate
a trajectory) and control covariates.
To maximise the number of people eligible,
the first available post-index reading taken at
least 76 days after the switch to alogliptin was
used. For the HbA1c trajectory analysis, at least
two HbA1c records during the pre-index period
were required, with the first result at least
90 days after the original DPP-4 inhibitor initi-
ation and a later result at least 60 days after the
first result, to allow a reasonable estimate of pre-
index HbA1c trajectory.
Secondary Endpoints
If the primary analysis demonstrated that the
switch to alogliptin was not associated with a
detrimental shift in glycaemic control, we
would then go on to determine the persistence
of alogliptin therapy at 6 months, the propor-
tion of people switched back to an alternative
DPP-4 inhibitor within 6 months, and the per-
centage of switched people who received fur-
ther intensification of their diabetes therapy
within 6 months of the switch. Finally, we
would perform a cost-effectiveness analysis to
determine the potential impact of the switch on
drug acquisition cost compared to the potential
cost of facilitating the switch.
Sensitivity Analysis
A sensitivity analysis was performed, excluding
people with very poor glycaemic control, evi-
denced by their last pre-switch HbA1c reading
(collected within 90 days of the switch)
exceeding 9% (75 mmol/mol) or 10%
(86 mmol/mol). All other aspects remained the
same as for the main analysis. Finally, an anal-
ysis would be performed stratified by baseline
HbA1c in 0.5% (5.5 mmol/mol) silos.
Statistical Analysis
Outcomes of interest were evaluated using
descriptive statistics, including mean, standard
deviation (SD), median, interquartile range
(IQR), minimum and maximum, 95% confi-
dence interval (CI) and frequency of missing
data for continuous variables, and frequency
and percentage of the sample population for
categorical variables. All statistical analyses were
performed using R version 3.4.2.
Differences between pre- and post-index
HbA1c measurements were compared using a
paired t test. Adjustments were made for CCG
locality, patient age and gender. A generalised
linear mixed effects model was used to assess
changes in HbA1c trajectory as a function of
switching to alogliptin (second co-primary
outcome), with HbA1c level as the dependent
variable, time (split into pre- and post-index
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periods) as a fixed effects variable and CCG as a
random effects variable. Baseline characteristics
were assessed as potential explanatory variables.
An interaction term between period (pre- vs
post-index) and any change in concomitant
therapy was assessed. Data are presented as
coefficient estimates and their associated 95%
CIs.
RESULTS
Data were extracted for 1085 people with dia-
betes who had undergone a switch from
another DPP-4 inhibitor to alogliptin, within its
licensed indication. Of these, 220 did not have
appropriate HbA1c results available either prior
to or within 6 months after the switch; there-
fore it was not possible to include these people
in the primary analysis. The characteristics at
the index point (day of switch) of the remaining
865 (63.7% male) are shown in Table 1. They
were a typical primary care population with
T2DM, with a mean HbA1c of 68.8 mmol/mol
(8.44%), blood pressure of 133/74 and total
cholesterol of 4.1 mmol/L. Concomitant medi-
cation use was predominantly with metformin
(39.08%), sulphonylurea (13.41%) or a combi-
nation of the two (45.43%). As expected, a
minority had proven atherosclerotic disease
(0.2% with cardiovascular disease, 3.1% with
peripheral vascular disease and 6.0% with prior
stroke). The switch to alogliptin did not have
any material impact on HbA1c with the post-
switch mean value being 68.6 mmol/mol
(8.42%). Data on prior DPP-4 inhibitor therapy
was available for 684 of 865 people (79.08%).
Time elapsed between the final prescription of
the pre-switch DPP-4 inhibitor and index date
varied substantially between people (median
63 days, IQR 30–272 days, min 1 day, max
2294 days), suggesting significant non-adher-
ence. We therefore restricted this analysis to
those who had a pre-switch DPP-4 inhibitor
prescribed within 90 days prior to switch to
alogliptin (n = 386). Among these patients,
HbA1c did not change significantly following
the switch [0.10% (95% CI - 0.03 to 0.23),
p = 0.14; Fig. 1]. Neither previous DPP-4 inhi-
bitor prescription nor concomitant medication
use had any clinically relevant impact on the
effect of the switch to alogliptin on glycaemic
control.
For the co-primary outcome examining the
impact of the switch on the trajectory of HbA1c,
sufficient HbA1c values were available for 319
people, with the principle reason for non-in-
clusion being an absence of two HbA1c values at
least 60 days apart prior to the switch. There
were no significant or clinically relevant differ-
ences between those included in this analysis
and those included in the primary endpoint
analysis (n = 865) (Supplementary Table 1).
When the trajectory models were generated,
significant predictors of a steeper (rising) HbA1c
trajectory were rising eGFR (p = 0.006), rising
total cholesterol (p\ 0.0001) and increasing
number of diabetes therapies (p\0.0001). Total
number of non-diabetes medications did not
have any impact on the trajectory of glycaemic
control. Interestingly history of a recent stroke
was associated with an improving HbA1c
(p = 0.008), but this was not replicated with
peripheral vascular disease, cardiovascular dis-
ease, nephropathy or retinopathy. Performing a
switch to alogliptin had no significant impact
on the trajectory of HbA1c, with the actual
mean value at 3 months being 8.33% vs pro-
jected HbA1c of 8.31%.
Sensitivity Analyses
Excluding participants with a baseline HbA1c
above 9% and above 10% (in whom it may have
been more appropriate to escalate therapy
rather than performing a simple switch) made
little difference to the change in HbA1c after the
switch [- 0.02% (95% CI - 0.10 to 0.10%] and
0.07% [- 0.03 to 0.17%] for baseline of B 10%
and B 9%, respectively).
When the impact of switch stratified by
baseline HbA1c was explored, there was a trend
that those who started with the best glycaemic
control had a modest deterioration in control,
whereas those with the poorest control saw a
small improvement in control (Fig. 2). This
interaction, however, did not reach statistical
significance.
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Secondary Analyses
Out of 865 people in the primary analysis, 705
(80.76%) continued alogliptin treatment at
6 months following the switch from another
DPP-4 inhibitor. There was a preponderance of
men who persisted on alogliptin (83.7% vs
75.6% for male vs female, respectively). Other-
wise there were no identified predictors of those
most likely to persist on alogliptin to 6 months.
Of the 168 who discontinued alogliptin over
the first 6 months, the majority (n = 132;
78.6%) were not switched to another DPP-4
inhibitor. Of the 705 who remained on
alogliptin, 32 people had additional non-DPP-4
inhibitor therapy added. The most common
additions were sulphonylurea (n = 8 people
with diabetes), SGLT-2 inhibitors (n = 8) and
metformin (n = 7).
When the financial impact of switching to
alogliptin was considered, sufficient details
regarding prescriptions before and after switch
were available for 349 people. These were pre-
dominantly switched from sitagliptin. The total
saving in acquisition costs over 6 months was
£15,005.76, based on acquisition costs stated in
the British National Formulary (BNF) [12], rep-
resenting a 19.9% saving in total prescribing
Table 1 Characteristics of the patient populations analysed
Variable All (n = 865)
People with missing data, n (%) Mean (SD) or n (%)
Change in HbA1c (percentage points) 0 (0.00%) - 0.02 (1.38)
HbA1c pre-switch (%) 0 (0.00%) 8.44 (1.52)
Weight (kg) 4 (0.46%) 90.13 (19.53)
Height (cm) 97 (11.21%) 169.57 (9.59)
Systolic blood pressure (mmHg) 0 (0.00%) 132.91 (14.22)
Diastolic blood pressure (mmHg) 0 (0.00%) 74.19 (9.00)
eGFR (ml/min/1.73 m2) 4 (0.46%) 64.64 (15.74)
Cholesterol: total (mmol/L) 0 (0.00%) 4.13 (0.99)
Cholesterol: HDL (mmol/L) 120 (13.87%) 1.15 (0.30)
Cholesterol: LDL (mmol/L) 283 (32.72%) 2.27 (2.14)
Age at switch (years) 0 (0.00%) 64.35 (11.19)
History of CVD 0 (0.00%) 2 (0.23%)
History of PVD 0 (0.00%) 27 (3.12%)
History of stroke 0 (0.00%) 52 (6.01%)
History of CKD 0 (0.00%) 138 (15.95%)
History of diabetic retinopathy 0 (0.00%) 47 (5.43%)
History of diabetic mononeuropathy 0 (0.00%) 1 (0.12%)
Male gender 0 (0.00%) 551 (63.70%)
CKD chronic kidney disease, CVD cardiovascular disease, DBP diastolic blood pressure, HbA1c glycated haemoglobin, eGFR
estimated glomerular filtration rate, HDL high-density lipoprotein, LDL low-density lipoprotein, PVD peripheral vascular
disease, SBP systolic blood pressure, SD standard deviation
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cost for these 349 people (median £7.24 per
person per month). There was no change in
documented primary care attendances nor in
number of investigations requested for the
individuals that underwent the switch. How-
ever, since duration of consultations is not
included in the electronic patient records, it is
not possible to estimate any cost implications of
service provision in order to perform a switch.
DISCUSSION
We have explored for the first time the impact
of a within-class drug switch program in dia-
betes, designed to reduce prescribing costs and
undertaken in a real-world setting. We demon-
strated that glycaemic control did not alter sig-
nificantly either in absolute terms or from
anticipated trajectory as a result of switching
from other DPP-4 inhibitors to alogliptin;
however, this switch is associated with a
reduction in drug acquisition cost of approxi-
mately 20%. The majority (80%) of people per-
sisted on alogliptin for at least 6 months and
few of these people received further diabetes
therapies, suggesting that the switch to alo-
gliptin rarely prompted further therapy change
or intensification. Among people who did not
maintain the switch to alogliptin, the majority
discontinued DPP-4 inhibitors altogether, sug-
gesting that the prescribing physicians rarely
considered costlier DPP-4 inhibitors to be more
appropriate treatment options than alogliptin.
Similar results were obtained in a sensitivity
analysis excluding people with very poor gly-
caemic control (i.e. those with an HbA1c read-
ing [9% or [ 10% within 90 days prior to
Fig. 1 Change in HbA1c from most recent pre-switch
measurement to first post-switch measurement by pre-
switch DPP-4 inhibitor prescribed, restricted to last
prescription issued within 90 days pre-switch. Data points
represent the mean difference in HbA1c and error bars the
95% CI. The vertical dotted grey line represents the
difference between pre- and post-switch HbA1c level
across all patients. The distribution of prior DPP-4 use was
sitagliptin 68.4%, vildagliptin 19.7%, linagliptin 6.7% and
saxagliptin 5.1%. CI confidence interval, HbA1c glycated
haemoglobin
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switch), where no statistically significant or
clinically meaningful change in HbA1c level
following treatment switch was observed.
Projected HBA1c trajectory was significantly
affected by people’s renal function, total
cholesterol level, history of stroke and the
number of diabetes therapies prescribed. As may
be anticipated, predicted HbA1c was positively
associated with renal function (higher eGFR),
high total cholesterol levels (a measure of
adherence to statin therapy) and a higher
number of diabetes therapies. Paradoxically,
however, predicted HbA1c was lower in people
with a history of stroke, potentially represent-
ing the impact of the complications of diabetes
on adherence to therapies.
On the basis of previous studies, baseline
HbA1c (supplemented by fasting plasma glu-
cose level), and not the type of DPP-4 inhibitor
used, is the strongest predictor of response to
DPP-4 inhibitor [13, 14]. The sequential intro-
duction of DPP-4 inhibitors, on a background of
the greater understanding of the impact of
adverse glycaemic legacy, resulted in the pro-
gressive improvement of background glycaemic
control over time, with the baseline HbA1c in
the first regulatory study being 8.7% for vilda-
gliptin add-on to metformin, whereas baseline
HbA1c levels in subsequent studies were
reduced to 8.2% for saxagliptin, 8.1% for sita-
gliptin and 7.9% for alogliptin. As a result the
potential for reduction in glycaemia was evi-
dently reduced with progressive molecule
introductions. The paucity of head-to-head tri-
als comparing different DPP-4 inhibitors makes
real-world studies that address the issue of their
interchangeability particularly valuable. The
present study suggests that in routine UK prac-
tice, the DPP-4 inhibitor alogliptin is indeed
interchangeable with other DPP-4 inhibitors.
This finding is in line with the conclusions of a
systematic review and network meta-analysis
which showed similar efficacy and safety across
the DPP-4 inhibitor class [15].
The sensitivity analysis suggested that pre-
treatment HbA1c predicted response to the
Fig. 2 Change in HbA1c following the switch to alogliptin by baseline HbA1c level. Bullets represent mean HbA1c levels;
the size of the bullets corresponds to the size of each patient group. HbA1c glycated haemoglobin
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alogliptin switch, with people experiencing a
post-switch decrease in HbA1c having higher
baseline HbA1c levels. This may, in part, have
been due to people with poor adherence (and
thus higher HbA1c) having their motivation to
engage with their therapy improved by the
active switch from previous DPP-4 inhibitor to
the new agent. Indeed, the engagement itself
may have improved therapeutic adherence.
However, for those at ideal glycaemic control
(HbA1c B 53 mmol/mol) the switch to aloglip-
tin was associated with a (non-significant)
marginal increase in HbA1c. This suggests that
while people not at target are not adversely
affected, indeed may benefit from, the process
of switching to alogliptin, those at optimal
control do not benefit, indeed may be adversely
affected by the switch. In terms of economic
impact, the switch to alogliptin provided a
median cost saving of £7.24 per person per
month in those individuals that had collected
prescriptions within the 3 months prior to the
switch.
Study Limitations
Based on a large sample of people treated in UK
primary care, this study provides real-world
evidence on the interchangeability of alogliptin
with other DPP-4 inhibitors. However, limita-
tions of the study include a relatively short
follow-up (median of 251 days for most analy-
ses) that may have been insufficient to capture
the need for therapy escalation in all people.
Further, the impacts of different treatment
doses were not investigated. We do not believe
that this represents a significant limitation,
however, since DPP-4 inhibitors (as a class) do
not require upwards dose titration, rather they
are initiated at optimal dose, then require dose
or frequency reduction in those with renal
impairment (with the exception of linagliptin).
CONCLUSIONS
We have demonstrated, for the first time, that
the in-class switch from other DPP-4 inhibitors
to alogliptin did not compromise clinical out-
comes and was generally well tolerated, but
potentially reduced DPP-4 inhibitor acquisition
costs by approximately 20%. Results from this
study suggest that alogliptin is clinically inter-
changeable with other DPP-4 inhibitors and
economically favourable, providing similar gly-
caemic control at a reduced cost.
Thus, switching people to alogliptin, where
clinically appropriate, generates cost-savings
with no adverse impact on glycaemic control.
ACKNOWLEDGEMENTS
W. David Strain would like to acknowledge the
support of the NIHR Exeter Clinical Research
Facility and the NIHR Collaboration for Lead-
ership in Applied Health Research and Care
(CLAHRC) for the South West Peninsula.
W. David Strain would like to add that the views
expressed in this publication are those of the
authors and not necessarily those of the NIHR
Exeter Clinical Research Facility, the NHS, the
NIHR or the Department of Health in England.
All author would also like to acknowledge the
staff and patients of the six CCGs that have
allowed their data to be used in this anonymous
manner.
Funding. The study was sponsored and
funded (including the journal’s Rapid Ser-
vice Fee) by Takeda UK Ltd.
Editorial Assistance. We are grateful to
Minesh Unadkat for editorial support of the
completed text.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of
the work as a whole, and have given their
approval for this version to be published.
Disclosures. W. David Strain holds research
grants from AstraZeneca, Bayer, Novo Nordisk
and Novartis, and has received speaker hono-
raria from AstraZeneca, Bristol Myer Squibb,
Merck, Napp, Novartis, Novo Nordisk, and
Takeda. Phil McEwan has received substantial
1506 Diabetes Ther (2019) 10:1499–1507
grant income from Takeda Pharmaceuticals in
relation to this study. Heena Howitt is an
employee of Takeda Pharmaceuticals. Simon
Meadowcroft is an employee of Takeda
Pharmaceuticals.
Compliance with Ethics Guidelines. This
analysis was performed with the approval of the
Caldicott Guardians from the respective CCGs,
the UK Confidentiality Advisory Group and the
South West Regional Ethics Committee (ap-
proval number 17/SW/001) in accordance with
the principles of the Helsinki Declaration of
1964 and its further amendments. All authors
had full access to all of the data in this study
and take complete responsibility for the integ-
rity of the data and accuracy of the data
analysis.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Zheng Y, Ley SH, Hu FB. Global aetiology and epi-
demiology of type 2 diabetes mellitus and its com-
plications. Nat Rev Endocrinol. 2018;14(2):88–98.
2. Diabetes UK. Diabetes prevalence. 2017. https://
www.diabetes.org.uk/professionals/position-stateme
nts-reports/statistics/diabetes-prevalence-2017. Acces-
sed 18 June 2019.
3. National Institute for Health and Care Excellence.
Type 2 diabetes in adults: management. NICE
guideline NG28. Algorithm for blood glucose low-
ering therapy in adults with type 2 diabetes. 2015;
Updated April 2017. https://www.nice.org.uk/
guidance/ng28/resources/algorithm-for-blood-gluc
ose-lowering-therapy-in-adults-with-type-2-diabetes
-pdf-2185604173. Accessed 18 June 2019.
4. Merck Sharp and Dohme Ltd. Summary of Product
Characteristics: sitagliptin phosphate monohydrate
(Januvia). Updated August 2018. https://www.
medicines.org.uk/emc/product/7887/smpc. Acces-
sed 18 June 2019.
5. Novartis Pharmaceuticals UK Ltd. Summary of
Product Characteristics: vildagliptin (Galvus).
Updated April 2018. https://www.medicines.org.
uk/emc/product/6225/smpc. Accessed 18 June
2019.
6. AstraZeneca UK Ltd. Summary of Product Charac-
teristics: saxagliptin hydrochloride (Onglyza).
Updated August 2018. https://www.medicines.org.
uk/emc/product/9368/smpc. Accessed 18 June
2019.
7. Boehringer Ingelheim Ltd. Summary of Product
Characteristics: linagliptin (Trajenta). Updated
March 2016. https://www.medicines.org.uk/emc/
product/4762/smpc. Accessed 18 June 2019.
8. Takeda UK Ltd. Summary of Product Characteris-
tics: alogliptin benzoate (Vipidia). Updated May
2018. https://www.medicines.org.uk/emc/product/
7571/smpc. Accessed 18 June 2019.
9. Green JB, Bethel MA, Armstrong PW, et al. Effect of
sitagliptin on cardiovascular outcomes in type 2
diabetes. N Engl J Med. 2015;373(3):232–42.
10. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin
and cardiovascular outcomes in patients with type
2 diabetes mellitus. N Engl J Med.
2013;369(14):1317–26.
11. White WB, Cannon CP, Heller SR, et al. Alogliptin
after acute coronary syndrome in patients with type
2 diabetes. N Engl J Med. 2013;369(14):1327–35.
12. Joint Formulary Committee. BNF 74. London:
Pharmaceutical Press; 2017.
13. Esposito K, Chiodini P, Maiorino MI, et al. A
nomogram to estimate the HbA1c response to dif-
ferent DPP-4 inhibitors in type 2 diabetes: a sys-
tematic review and meta-analysis of 98 trials with
24 163 patients. BMJ Open. 2015;5(2):e005892.
14. Esposito K, Chiodini P, Capuano A, Maiorino MI,
Bellastella G, Giugliano D. Baseline glycemic
parameters predict the hemoglobin A1c response to
DPP-4 inhibitors: meta-regression analysis of 78
randomized controlled trials with 20,053 patients.
Endocrine. 2014;46(1):43–51.
15. Craddy P, Palin HJ, Johnson KI. Comparative
effectiveness of dipeptidylpeptidase-4 inhibitors in
type 2 diabetes: a systematic review and mixed
treatment comparison. Diabetes Ther.
2014;5(1):1–41.
Diabetes Ther (2019) 10:1499–1507 1507
